154 related articles for article (PubMed ID: 38175449)
1. Targeted axillary dissection: worldwide variations in clinical practice.
Kontos M; Kanavidis P; Kühn T; Masannat Y; Gulluoglu B;
Breast Cancer Res Treat; 2024 Apr; 204(2):389-396. PubMed ID: 38175449
[TBL] [Abstract][Full Text] [Related]
2. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
[TBL] [Abstract][Full Text] [Related]
4. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
6. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
8. Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment.
Natsiopoulos I; Intzes S; Liappis T; Zarampoukas K; Zarampoukas T; Zacharopoulou V; Papazisis K
Clin Breast Cancer; 2019 Jun; 19(3):208-215. PubMed ID: 30922804
[TBL] [Abstract][Full Text] [Related]
9. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
[TBL] [Abstract][Full Text] [Related]
13. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
[TBL] [Abstract][Full Text] [Related]
14. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
[TBL] [Abstract][Full Text] [Related]
15. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
16. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Yang X; Li Y; Ren XT; Fan L; Hua B
World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
[TBL] [Abstract][Full Text] [Related]
17. Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain.
Munoz P; Corral S; Martínez-Regueira F; Paz A; Muñoz-Madero V; Mena A; Cabañas J; Rivas S
Clin Transl Oncol; 2023 May; 25(5):1463-1471. PubMed ID: 36586064
[TBL] [Abstract][Full Text] [Related]
18. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
19. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
[TBL] [Abstract][Full Text] [Related]
20. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.
Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L
Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
